Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation FDA Approvals

US FDA Announces Trial-Focused Spinal Devices Workshop

  • News

Executive Summary

The 17 September session will home in on the details of spinal device regulation, including adverse event reporting and efforts to increase diversity in study populations.

You may also be interested in...



Medtech Backs US Supreme Court Decision Upholding Affordable Care Act

Health care industry groups expressed support after the high court found that Texas and 17 other Republican-led states lacked standing to file suit because they hadn’t shown the act had directly harmed them.

BD Sues Beckman Coulter Over Flow Cytometry Patents

Becton Dickinson claims Beckman Coulter has been knowingly violating several patents since at least 2015.

StrataGraft Topical Burn Treatment Gets US FDA Approval

The topical treatment is made from human skin cells and can be applied to speed the healing of deep thermal burns.

Table

View full table

Topics

Tags:
Regulation FDA Approvals
UsernamePublicRestriction

Register

MT144030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By